Months › 1999
Month received
November 1999: adverse event reports received
2,420 reports in the openFDA release of 28 Sep 2026
FDA's database holds 2,420 adverse event reports received in November 1999, against 658 in the same month a year earlier and a monthly average of 990 over the preceding 12 months.
81.5% of the month's reports concern dogs, 4% cats and 2.3% horses; the rest concern other species, exposed people, or give no species.
By active ingredient, the drugs named most often were carprofen (1,733), ampicillin trihydrate (57) and tilmicosin phosphate (52), and the terms listed most often were elevated alanine aminotransferase (ALT) (456), elevated serum alkaline phosphatase (SAP) (435) and vomiting (427). Report volume has a seasonal shape, with more reports in the warmer months when parasite products are in heavier use.
The months around it
Drugs named most often, by active ingredient
| Active ingredients recorded for the drug | Reports | Share of the month's reports |
|---|---|---|
| Carprofen | 1,733 | 71.6% |
| Ampicillin Trihydrate | 57 | 2.4% |
| Tilmicosin Phosphate | 52 | 2.1% |
| Selamectin | 51 | 2.1% |
| Etodolac | 47 | 1.9% |
| Amoxicillin | 46 | 1.9% |
| Moxidectin | 41 | 1.7% |
| Milbemycin Oxime | 36 | 1.5% |
| Selegiline Hydrochloride | 35 | 1.4% |
| Ketamine Hydrochloride | 22 | 0.9% |
| Lufenuron + Milbemycin Oxime | 21 | 0.9% |
| Dinoprost Tromethamine | 17 | 0.7% |
| Lufenuron | 17 | 0.7% |
| Tiletamine Hydrochloride + Zolazepam Hydrochloride | 13 | 0.5% |
| Medetomidine | 11 | 0.5% |
Ordered by report count, which follows how widely each drug was in use. FDA states that these data cannot be used to estimate risk or to compare one product with another. Brand and manufacturer names are masked by FDA in these records.
Signs listed most often
- Elevated alanine aminotransferase (ALT)[a liver enzyme above the normal range]18.8%456
- Elevated serum alkaline phosphatase (SAP)[a liver and bone enzyme above the normal range]18%435
- Vomiting17.6%427
- Anorexia[not eating]15.7%379
- Depression[dull, quiet or withdrawn]10.8%261
- Elevated total bilirubin[bilirubin above the normal range]8.1%195
- Diarrhoea[diarrhea]7%170
- Accidental exposure[exposure that was not intended]6.4%155
- Convulsion[seizure]5.2%127
- Elevated blood urea nitrogen (BUN)[a kidney value above the normal range]5%120
- No sign[no clinical sign was reported]4.6%111
- Elevated creatinine[a kidney value above the normal range]4.5%109
- Icterus[jaundice (yellowing)]4.3%105
- Ataxia[unsteady, uncoordinated movement]4.3%103
- Elevated aspartate aminotransferase (AST)[a liver and muscle enzyme above the normal range]4.3%103
Single ingredients, pooled
Species
Questions about November 1999
How many animal drug adverse event reports did FDA receive in November 1999?
2,420 reports are in the openFDA release of 28 Sep 2026. The same month a year earlier has 658.
Which drugs were named most often?
By active ingredient: carprofen (1,733), ampicillin trihydrate (57), tilmicosin phosphate (52), selamectin (51) and etodolac (47). Brands are masked in the public data.
Which signs were listed most often?
elevated alanine aminotransferase (ALT) (456), elevated serum alkaline phosphatase (SAP) (435), vomiting (427), anorexia (379) and depression (261).
Can the count for a month still change?
Yes. FDA posts reports quarterly with a delay of three to six months, so the newest months are incomplete and usually grow in later releases. Older months change little.
Does a busy month mean something went wrong that month?
Not by itself. The date is when FDA received the report, not when the event happened, and volume follows season, product launches and publicity. FDA states that "there is no certainty that the reported drug or device caused the adverse event" and that the event "may have been related to an underlying disease, other drugs used at the same time or other non-drug related sources."
Where this comes from. Counts are built from the openFDA Animal & Veterinary adverse event bulk files released 28 Sep 2026, which hold reports FDA's Center for Veterinary Medicine received through 31 Mar 2026. openFDA masks brand and manufacturer names in these files, so drugs are counted by the active ingredients each record discloses and no figure is attributed to a brand, application or company. Ingredient names, and the separate reference lists of approved products, follow the FDA Green Book as of 1 Oct 2026. The month is the date FDA first received the report, not the date of the event. No report text, lot numbers or reporter details are published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.